FOI release

Final Clinical Study Report for CTA 18024-0212-001

This request was refused in part, so we didn't provide some of the information the requester asked for. This may include information where we can neither confirm nor deny that we hold it.

Case reference FOI2026/00801

Received 22 July 2026

Published 9 September 2026

Request

Further to FOI2026/00663, please treat this email as a new, narrowed FOI request. We request disclosure of the Final Clinical Study Report for CTA 18024-0212-001 relating to THCV, limited to: • final safety conclusions, • aggregate adverse event tables, • anonymised non-clinical or clinical safety summaries, • and any other severable non-confidential content. We are content for redactions to be applied where necessary and do not seek sponsor-identifying, confidential, or commercially sensitive material. If the full report cannot be disclosed, please provide any releasable portions of it.

Response

See attached

Documents

• FOI2026_00801 (redacted).pdf (778.2 KB)

This is Medicines and Healthcare products Regulatory Agency's response to a freedom of information (FOI) or environmental information regulations (EIR) request.

You can browse our other responses or make a new FOI request.